Refining the anticoagulation approach in COVID-19: Interim results of three trials

Therapeutic anticoagulation appears to be beneficial in patients with moderate COVID-19, but not in those with severe disease where it may actually do harm, interim results from three large international trials suggest. Initial data from ATTACC, REMAP-CAP and ACTIV-4a suggests that in patients who are hospitalised and require oxygen but not ICU organ support, therapeutic ...

Already a member?

Login to keep reading.

© 2021 the limbic